Literature DB >> 31758575

Screening for iron deficiency in surgical patients based on noninvasive zinc protoporphyrin measurements.

Christoph Füllenbach1, Philipp Stein2, Patricia Glaser1, Chris Triphaus1, Simone Lindau1, Suma Choorapoikayil1, Elke Schmitt1, Kai Zacharowski1, Gudrun Hintereder3, Georg Hennig4,5, Christian Homann4,5, Herbert Stepp4,5, Gabriela H Spahn2, Alexander Kaserer2, Andreas Schedler2, Patrick Meybohm1,6, Donat R Spahn2.   

Abstract

BACKGROUND: Approximately every third surgical patient is anemic. The most common form, iron deficiency anemia, results from persisting iron-deficient erythropoiesis (IDE). Zinc protoporphyrin (ZnPP) is a promising parameter for diagnosing IDE, hitherto requiring blood drawing and laboratory workup. STUDY DESIGN AND METHODS: Noninvasive ZnPP (ZnPP-NI) measurements are compared to ZnPP reference determination of the ZnPP/heme ratio by high-performance liquid chromatography (ZnPP-HPLC) and the analytical performance in detecting IDE is evaluated against traditional iron status parameters (ferritin, transferrin saturation [TSAT], soluble transferrin receptor-ferritin index [sTfR-F], soluble transferrin receptor [sTfR]), likewise measured in blood. The study was conducted at the University Hospitals of Frankfurt and Zurich.
RESULTS: Limits of agreement between ZnPP-NI and ZnPP-HPLC measurements for 584 cardiac and noncardiac surgical patients equaled 19.7 μmol/mol heme (95% confidence interval, 18.0-21.3; acceptance criteria, 23.2 μmol/mol heme; absolute bias, 0 μmol/mol heme). Analytical performance for detecting IDE (inferred from area under the curve receiver operating characteristics) of parameters measured in blood was: ZnPP-HPLC (0.95), sTfR (0.92), sTfR-F (0.89), TSAT (0.87), and ferritin (0.67). Noninvasively measured ZnPP-NI yielded results of 0.90.
CONCLUSION: ZnPP-NI appears well suited for an initial IDE screening, informing on the state of erythropoiesis at the point of care without blood drawing and laboratory analysis. Comparison with a multiparameter IDE test revealed that ZnPP-NI values of 40 μmol/mol heme or less allows exclusion of IDE, whereas for 65 μmol/mol heme or greater, IDE is very likely if other causes of increased values are excluded. In these cases (77% of our patients) ZnPP-NI may suffice for a diagnosis, while values in between require analyses of additional iron status parameters.
© 2019 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31758575     DOI: 10.1111/trf.15577

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  4 in total

Review 1.  [Patient blood management in the preparation for birth, obstetrics and postpartum period].

Authors:  Philipp Helmer; Tobias Schlesinger; Sebastian Hottenrott; Michael Papsdorf; Achim Wöckel; Joachim Diessner; Jan Stumpner; Magdalena Sitter; Tobias Skazel; Thomas Wurmb; Christoph Härtel; Stefan Hofer; Ibrahim Alkatout; Thierry Girard; Patrick Meybohm; Peter Kranke
Journal:  Anaesthesist       Date:  2022-03-02       Impact factor: 1.041

2.  The Importance of Iron Administration in Correcting Anaemia After Major Surgery.

Authors:  Mirela Tiglis; Cristian Cobilinschi; Liliana Elena Mirea; Alexandru Emil Băetu; Ileana Peride; Tiberiu Paul Neagu; Andrei Niculae; Ionel Alexandru Checherită; Ioana Marina Grintescu
Journal:  J Crit Care Med (Targu Mures)       Date:  2021-08-05

3.  Iron deficiency and biomarkers of inflammation: a 3-year prospective analysis of the DO-HEALTH trial.

Authors:  Maud Wieczorek; Franziska Schwarz; Angélique Sadlon; Lauren A Abderhalden; Caroline de Godoi Rezende Costa Molino; Donat R Spahn; Dominik J Schaer; E John Orav; Andreas Egli; Heike A Bischoff-Ferrari
Journal:  Aging Clin Exp Res       Date:  2021-09-17       Impact factor: 3.636

4.  Prevalence and incidence of iron deficiency in European community-dwelling older adults: an observational analysis of the DO-HEALTH trial.

Authors:  Alenka Stahl-Gugger; Caroline de Godoi Rezende Costa Molino; Maud Wieczorek; Patricia O Chocano-Bedoya; Lauren A Abderhalden; Dominik J Schaer; Donat R Spahn; E John Orav; Bruno Vellas; José A P da Silva; Reto W Kressig; Andreas Egli; Heike A Bischoff-Ferrari
Journal:  Aging Clin Exp Res       Date:  2022-03-18       Impact factor: 4.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.